ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,595
0,07%
Bitcoin
59 078,75
1,44%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Ambrx Biopharma Inc (AMAM)

  7. Ambrx Biopharma Inc (AMAM) Actualités

AMAM

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:AMAM
DateHeureSourceTitreSymboleSociété
12/10/202322h20Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:AMAMAmbrx Biopharma Inc
12/10/202312h04Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMAMAmbrx Biopharma Inc
10/10/202317h35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNYSE:AMAMAmbrx Biopharma Inc
07/07/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMAMAmbrx Biopharma Inc
28/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:AMAMAmbrx Biopharma Inc
28/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NYSE:AMAMAmbrx Biopharma Inc
25/05/202322h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:AMAMAmbrx Biopharma Inc
18/05/202322h28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:AMAMAmbrx Biopharma Inc
16/05/202322h07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NYSE:AMAMAmbrx Biopharma Inc
11/05/202322h08Edgar (US Regulatory)Quarterly Report (10-q)NYSE:AMAMAmbrx Biopharma Inc
05/05/202322h06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:AMAMAmbrx Biopharma Inc
28/04/202322h22Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:AMAMAmbrx Biopharma Inc
28/04/202322h09Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:AMAMAmbrx Biopharma Inc
27/04/202322h11Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:AMAMAmbrx Biopharma Inc
18/04/202322h16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:AMAMAmbrx Biopharma Inc
03/04/202312h18Edgar (US Regulatory)Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)NYSE:AMAMAmbrx Biopharma Inc
30/03/202323h23Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NYSE:AMAMAmbrx Biopharma Inc
30/03/202322h10Edgar (US Regulatory)Annual Report (10-k)NYSE:AMAMAmbrx Biopharma Inc
16/03/202322h14Edgar (US Regulatory)Certification by the Exchange Approving Securities for Listing (cert)NYSE:AMAMAmbrx Biopharma Inc
16/03/202321h37Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NYSE:AMAMAmbrx Biopharma Inc
16/03/202321h07Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:AMAMAmbrx Biopharma Inc
16/03/202321h07Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NYSE:AMAMAmbrx Biopharma Inc
16/12/202223h24Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NYSE:AMAMAmbrx Biopharma Inc
11/12/202218h37TipRanksMeet the Biotech Stock That Jumped Over 1000% in One DayNYSE:AMAMAmbrx Biopharma Inc
11/12/202218h25TipRanksCowen & Co. Keeps Their Buy Rating on Ambrx Biopharma (AMAM)NYSE:AMAMAmbrx Biopharma Inc
09/12/202216h36TipRanksAMAM Pops After Positive Clinical Trial DataNYSE:AMAMAmbrx Biopharma Inc
09/11/202214h00Business WireAmbrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70NYSE:AMAMAmbrx Biopharma Inc
01/11/202221h05Business WireAmbrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive OfficerNYSE:AMAMAmbrx Biopharma Inc
18/10/202222h05GlobeNewswire Inc.Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate UpdateNYSE:AMAMAmbrx Biopharma Inc
11/10/202222h05GlobeNewswire Inc.Ambrx Biopharma to Host Corporate Update Conference CallNYSE:AMAMAmbrx Biopharma Inc
 Showing the most relevant articles for your search:NYSE:AMAM

Dernières Valeurs Consultées

EU
VK
Vallourec
EU
AI
Air Liquide
EU
PX4
SBF 120
EU
BEL20
Bel 20
COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
EU
BNP
BNP Paribas
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
EU
VIV
Vivendi
EU
ML
Michelin
EU
BN
Danone
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés